In 2004, another 30 biotech and specialty pharma firms completed IPOs in the U.S. market and 15 more came public in other areas of the world, including India, Australia and the U.K. As well, 43 companies raised money through follow-on offerings in 2004. Together, the IPOs and follow-on offerings raised a cool $5.6 billion – the biggest haul for public offerings since the glory days of 2000, when IPOs and follow-ons took in $18.4 billion.

As a service to its readers, Signals published this article in early January 2004 to track U.S.-based public financings for the year. Throughout the year we updated the lists on a continuous basis. We tracked the progress of each IPO and follow-on offering and also kept a log of those offerings that were postponed or withdrawn.

What follows is the completed list of all public offerings made on U.S. exchanges in 2004. If you’d like to track public financing in 2005, please refer to the Signals article, “Red Herrings & Green Shoes.”

To make it easier for you to navigate this article, we’ve provided some internal links. The section that covers IPOs that priced follows directly. To check out the follow-on offerings, click here. For withdrawals and postponements, click here.

Completed IPOs

§ Dec. 10, 2004: Adeza Biomedical Corp. (NASDAQ:ADZA): Developing diagnostics for women’s reproductive healthcare. Markets several tests, including Fetal Fibronectin Test (to determine the risk of preterm birth) and E-tegrity Test (infertility-related). On Dec. 10, priced 3.75M shares at $16.00 per share for gross proceeds of $60M. On Dec. 21, raised an additional $9M by selling the full overallotment (562,500 shares). Total gross proceeds: $69M. Underwriters: UBS Investment Bank (lead); SG Cowen; Thomas Weisel Partners; and William Blair & Co. First-day change: +23%.

§ Nov. 18, 2004: PRA International (NASDAQ:PRAI): Provides clinical research and development services to the pharmaceutical and biotech industries. On Nov. 18, priced 6M shares at $19.00 per share. Of those, the company sold 3.6M shares for gross proceeds of $68.4M and certain stockholders sold 2.4M shares for gross proceeds of $45.6M. Underwriters: Credit Suisse First Boston and Bear, Stearns & Co. (co-leads); William Blair & Co.; and Jefferies & Co. First-day change: +11%.

§ Oct. 15, 2004: CoTherix Inc. (NASDAQ:CTRX): Developing therapies for the treatment of cardiopulmonary and infectious diseases. Lead drug candidate Ventavis, an inhaled prostacyclin analog for treating pulmonary arterial hypertension, is currently marketed in Europe by Schering AG. The company licensed the U.S. rights from Schering and filed an NDA in June 2004. On Oct. 15, priced 5M shares at $6.00 per share for gross proceeds of $30M. Underwriters: CIBC World Markets and Piper Jaffray (co-leads), Needham & Co., and Thomas Weisel Partners. First-day change: +0.1%.

§ Oct. 5, 2004: Theravance Inc. (NASDAQ:THRX): Developing small molecule drugs based on clinically validated targets. Five product candidates resulting from the firm’s collaboration with GlaxoSmithKline on long-acting beta-2 agonists for treating asthma and COPD are in clinical trials. Theravance’s lead product candidates for bacterial infections and overactive bladder are also in the clinic. On Oct. 5, priced 6.15M shares at $16.00 per share for gross proceeds of $98.4M. On Oct. 8, raised an additional $14.8M by selling the full overallotment (922,500 shares). Total gross proceeds: $113.2M. Underwriters: Merrill Lynch & Co. and Lehman Brothers (co-leads); Credit Suisse First Boston; Perseus Group; and Thomas Weisel Partners. First-day change: +13%.

§ Aug. 5, 2004: New River Pharmaceuticals Inc. (NASDAQ:NRPH): A specialty pharmaceutical company that is developing improved versions of widely-prescribed amphetamine and opioid analgesic drugs. The most advanced compound, a prodrug of amphetamine, is in Phase I clinical trials. On Aug. 5, priced 4.2M shares at $8.00 per share for gross proceeds of $33.6M. Underwriters: WR Hambrecht + Co. (lead); First Albany Capital; Wells Fargo Securities; and Punk, Ziegel & Co. First-day change: -4%.

§ July 27, 2004: MannKind Corp. (NASDAQ:MNKD): Uses Technosphere formulation technology for formulating drugs for pulmonary delivery, primarily for treating metabolic and immunologic diseases. Lead product, the Technosphere Insulin System, is in late Phase II clinical trials for treating diabetes. On July 27, priced 6.25M shares at $14.00 per share for gross proceeds of $87.5M. On Aug. 28, raised an additional $4.3M by selling 307,100 shares (partial overallotment). Total gross proceeds: $91.8M. Underwriters: UBS Securities (sole book runner), Piper Jaffray (co-lead), Wachovia Securities, Jefferies & Co., and Harris Nesbitt Gerard. First-day change: 0%.

§ July 23, 2004: Auxilium Pharmaceuticals Inc. (NASDAQ:AUXL): A specialty pharmaceutical company that is developing drugs for treating urologic and sexual health disorders. The firm’s marketed product, Testim, is a topical testosterone gel for treating hypogonadism. On July 23, priced 5.5M shares at $7.50 per share for gross proceeds of $41.3M. Underwriters: Deutsche Bank Securities (lead), Piper Jaffray, and Thomas Weisel Partners. First-day change: -4%.

§ July 21, 2004: Idenix Pharmaceuticals Inc. (NASDAQ:IDIX): Developing nucleoside and nucleoside analogue-based therapeutics for viral diseases, including hepatitis B virus, hepatitis C virus and HIV. Lead drug candidate for HBV is in Phase III trials; two other candidates are in earlier-stage trials. On July 21, priced 5.8M shares at $14 per share. Of those, the company sold 4.6M shares for gross proceeds of $64.4M and certain stockholders sold 1.2M shares for gross proceeds of $16.8M. As well, corporate partner Novartis bought 5.4M shares at the public offering price in a private placement. Underwriters: Goldman, Sachs & Co. and Morgan Stanley (co-leads) and Bear, Stearns & Co. First-day change: -4%.

§ July 16, 2004: Xenogen Corp. (NASDAQ:XGEN): Developing an in vivo biophotonic imaging system that allows researchers to track and monitor the molecular mechanisms of disease and the impact of drugs on these mechanisms, as they occur, in live animals. On July 16, priced 4.2M shares at $7.00 per share for gross proceeds of $29.4M. Underwriters: Thomas Weisel Partners (lead), CIBC World Markets, and JMP Securities. First-day change: +7%.

§ June 21, 2004: Momenta Pharmaceuticals Inc. (NASDAQ:MNTA): The company specializes in sequencing and engineering complex sugars for the development of improved versions of existing drugs, the development of new drugs and the discovery of new biological processes. The company expects to submit an ANDA on its lead product, M-Enoxaparin, in the next 12 months. On June 21, priced 5.35M shares at $6.50 per share for gross proceeds of $34.8M. On June 28, raised an additional $5.2M by selling the full overallotment (802,500 shares). Total gross proceeds: $40M. Underwriters: SG Cowen and Banc of America Securities (joint book-running managers), CIBC World Markets and ThinkEquity Partners. First-day change: +20%.

§ June 21, 2004: Senomyx Inc. (NASDAQ:SNMX): Uses taste receptor-based assays and screening technologies to discover and develop flavors and flavor enhancers for the packaged food and beverage industry. On June 21, priced 6M shares at $6.00 per share for gross proceeds of $36M. In July, raised an additional $2.7M by selling 450,000 shares (partial overallotment). Total gross proceeds: $38.7M. Underwriters: Citigroup (sole book-running manager), Deutsche Bank Securities (co-lead), Needham & Co. and First Albany Capital. First-day change: +13%.

§ June 15, 2004: Metabasis Therapeutics Inc. (NASDAQ:MBRX): Developing small molecule drugs for treating liver diseases and metabolic diseases linked to pathways in the liver. Lead product candidate, CS-917 for treating Type II diabetes, is in Phase II clinical trials. Two other products are in the clinic for hepatitis B infection and primary liver cancer. On June 15, priced 5M shares at $7.00 per share for gross proceeds of $35M. On July 20, raised an additional $0.5M by selling 75,000 shares (partial overallotment). Total gross proceeds: $35.5M. Underwriters: SG Cowen Securities (sole book-runner); Deutsche Bank Securities (co-lead); Thomas Weisel Partners; and Legg Mason Wood Walker. First-day change: -5%.

§ June 3, 2004: Inhibitex Inc. (NASDAQ:INHX): Developing antibody-based therapies for the prevention and treatment of serious bacterial and fungal infections in hospitalized patients. Two product candidates are in the clinic, including Veronate, which is expected to enter Phase III clinical trials in the second half of 2004 as a therapy for preventing hospital-associated infections in premature, very low birth weight infants. On June 3, priced 5M shares at $7.00 per share for gross proceeds of $35M. On July 8, raised an additional $3.7M by selling 527,000 shares (partial overallotment). Total gross proceeds: $38.7M. Underwriters: Thomas Weisel Partners and Lazard Freres & Co. (joint book-running managers) and Harris Nesbitt Gerard. First-day change: +3%.

§ May 27, 2004: Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY): Developing RNA interference (RNAi)-based therapeutics that will be administered directly to disease sites. Research programs are focused on age-related macular degeneration and Parkinson’s disease. On May 27, priced 5M shares at $6.00 per share for gross proceeds of $30M. On June 7, raised an additional $4.5M by selling the full overallotment (750,000 shares). Total gross proceeds: $34.5M. Underwriters: Banc of America Securities (lead), Citigroup, Piper Jaffray and ThinkEquity Partners. First-day change: +0.2%.

§ May 26, 2004: ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD): Developing small molecule drugs, discovered via target- and chemistry-based platform, for treating central nervous system disorders. Lead product candidate is in Phase II clinical trials for treatment-induced dysfunction in Parkinson’s disease; two other drugs are about to enter Phase II trials in schizophrenia. On May 26, priced 5M shares at $7.00 per share for gross proceeds of $35M. Underwriters: Banc of America Securities (lead), Piper Jaffray, JMP Securities, and Adams, Harkness & Hill. First-day change: -4%.

§ May 26, 2004: Critical Therapeutics Inc. (NASDAQ:CRTX): Developing therapies that regulate the inflammatory response associated with asthma and critical care diseases. The company in-licensed the FDA-approved asthma drug Zyflo, as well as additional formulations of the active ingredient zileuton, from Abbott Laboratories. Its internal research programs target the cytokine cascade. On May 26, priced 6M shares at $7.00 per share for gross proceeds of $42M. Also in May, raised an additional $0.8M by selling 114,285 shares (partial overallotment). Total gross proceeds: $42.8M. Underwriters: SG Cowen Securities (lead), CIBC World Markets, Piper Jaffray, and Leerink Swann & Co. First-day change: +1%.

§ April 29, 2004: Cytokinetics Inc. (NASDAQ:CYTK): Developing small molecule drugs that target the cytoskeleton. Lead drug candidate SB-715992, which inhibits cell proliferation and promotes cancer cell death by disrupting the function of kinesin spindle protein, is in Phase II trials in non-small cell lung cancer. On April 29, priced 6.9M shares at $13.00 per share for gross proceeds of $89.7M. On May 4, raised an additional $13.5M by selling the full overallotment (1.035M shares). Total gross proceeds: $103.2M. Underwriters: Goldman, Sachs & Co. (lead), Credit Suisse First Boston, Pacific Growth Equities, and Lazard Freres & Co. First-day change: +24%.

§ April 28, 2004: Barrier Therapeutics Inc. (NASDAQ:BTRX): Spun out of the Johnson & Johnson family of companies in May 2002, Barrier is developing dermatology products. Eight product candidates are in the clinic, with four of them (for seborrheic dermatitis, diaper dermatitis, fungal infections and congenital ichthyosis) in or entering Phase III trials. On April 28, priced 5M shares at $15.00 per share for gross proceeds of $75M. Underwriters: Morgan Stanley (lead), Banc of America Securities, and JPMorgan Securities. First-day change: -3%.

§ April 15, 2004: Immunicon Corp. (NASDAQ:IMMC): Developing and commercializing research and diagnostic products for isolating, labeling, counting and analyzing tumor cells in the blood. On April 15, priced 6M shares at $8.00 per share for gross proceeds of $48M. On May 13, raised an additional $7.2M by selling the full overallotment (0.9M shares). Total gross proceeds: $55.2M. Underwriters: UBS Investment Bank (lead), SG Cowen Securities, Legg Mason Wood Walker and Adams, Harkness & Hill. First-day change: +19%.

§ April 14, 2004: Corcept Therapeutics Inc. (NASDAQ:CORT): Developing drugs for treating severe psychiatric and neurological diseases. The company’s lead product candidate, Corlux (a drug that selectively blocks the binding of cortisol to the GR-II receptor) is in Phase III clinical trials for treating psychotic major depression. On April 14, priced 4.5M shares at $12.00 per share for gross proceeds of $54M. Underwriters: Thomas Weisel Partners (lead), Piper Jaffray, and Legg Mason Wood Walker. First-day change: +2%.

§ April 5, 2004: Memory Pharmaceuticals Corp. (NASDAQ:MEMY): Developing therapeutics for treating CNS conditions that exhibit memory loss and other cognitive impairments. Two products are in early-stage clinical trials in Alzheimer’s disease. On April 5, priced 5M shares at $7.00 per share for gross proceeds of $35M. On April 20, raised an additional $5.3M by selling the full overallotment (750,000 shares). Total gross proceeds: $40.3M. Underwriters: UBS Investment Bank (lead), SG Cowen Securities, Banc of America Securities, and Fortis Securities. First-day change: +20%.

§ March 31, 2004: Santarus Inc. (NASDAQ:SNTS): A specialty pharmaceutical company that is developing proton pump inhibitor-based products for preventing and treating gastrointestinal diseases and disorders. The company submitted an NDA for its lead product, Rapinex (for treating upper GI disorders), in August 2003. On March 31, priced 6M shares at $9.00 per share for gross proceeds of $54M. On April 15, raised an additional $8.1M by selling the full overallotment (900,000 shares). Total gross proceeds: $62.1M. Underwriters: SG Cowen Securities and UBS Investment Bank (joint book-running managers), Thomas Weisel Partners, and RBC Capital Markets. First-day change: +12%.

§ March 25, 2004: Anadys Pharmaceuticals Inc. (NASDAQ:ANDS): Developing small molecule drugs that regulate innate immunity for treating hepatitis C virus and bacterial infections. Lead product, isatoribine, is in clinical trials for reducing the risk of HCV relapse in infected patients. On March 25, priced 6.25M shares at $7.00 per share for gross proceeds of $43.8M. On April 26, raised an additional $5.2M by selling 743,950 shares (partial overallotment). Total gross proceeds: $49M. Underwriters: SG Cowen Securities and Piper Jaffray (co-leads), Legg Mason Wood Walker and Needham & Co. First-day change: +0.8%.

§ March 16, 2004: Tercica Inc. (NASDAQ:TRCA): Developing recombinant human insulin-like growth factor-1 (in-licensed from Genentech) for the treatment of short stature, diabetes and other endocrine system disorders. Phase III trials in the first indication have been completed. On March 16, priced 5.5M shares at $9.00 per share for gross proceeds of $49.5M. On April 2, raised an additional $7.4M by selling the full overallotment (825,000 shares). Total gross proceeds: $56.9M. Underwriters: Lehman Brothers (sole book running manager), SG Cowen, Harris Nesbitt Gerard and Robert W. Baird. First-day change: 0%.

§ March 16, 2004: Xcyte Therapies Inc. (NASDAQ:XCYT): Developing therapeutics for cancer and infectious diseases by using patient's own T cells, which are activated ex vivo and then reinfused. Early-stage clinical trials ongoing in various cancers. On March 16, priced 4.2M shares at $8.00 per share for gross proceeds of $33.6M. Underwriters: Piper Jaffray (lead), RBC Capital Markets, Wells Fargo Securities and JMP Securities. First-day change: -9%.

§ Feb. 18, 2004: Dynavax Technologies Corp. (NASDAQ:DVAX): Developing therapeutics based on approaches for altering the immune system’s response to disease (allergies, infectious diseases and chronic inflammatory diseases). Three product candidates are in clinical trials. On Feb. 18, priced 6M shares at $7.50 per share for gross proceeds of $45M. On Feb. 24, raised an additional $6.8M by selling the full overallotment (0.9M shares). Total gross proceeds: $51.8M. Underwriters: Bear, Stearns & Co. and Deutsche Bank Securities (joint book-running managers) and Piper Jaffray. First-day change: +25%.

§ Feb. 11, 2004: Corgentech Inc. (NASDAQ:CGTK): Developing transcription factor decoys as therapeutics for cardiovascular disease, inflammatory disease and cancer. Lead product candidate E2F Decoy is in two Phase III clinical trials for preventing vein graft failure. On Feb. 11, priced 6M shares at $16 per share for gross proceeds of $96M. In March, the company raised an additional $14.4M by selling the full overallotment (900,000 shares). Total gross proceeds: $110.4M. Underwriters: Credit Suisse First Boston and Lehman Brothers (joint book-running managers), CIBC World Markets and U.S. Bancorp Piper Jaffray. First-day change: +34%.

§ Feb. 5, 2004: Renovis Inc. (NASDAQ:RNVS): Developing drugs for neurological diseases and disorders. Three product candidates are in the clinic, including Cerovive for treating acute ischemic stroke, which is in Phase III trials being conducted by licensee AstraZeneca plc. On Feb. 5, priced 5.5M shares at $12 per share for gross proceeds of $66M. In March, the company raised an additional $9.9M by selling the full overallotment (825,000 shares). Total gross proceeds: $75.9M. Underwriters: Goldman, Sachs & Co. (lead), CIBC World Markets, SG Cowen Securities and U.S. Bancorp Piper Jaffray. First-day change: + 21%.

§ Feb. 2, 2004: GTx Inc. (NASDAQ:GTXI): Developing small molecule therapeutics that modulate the effects of estrogens and androgens for treating serious men’s health conditions. Lead product candidate Acapodene is in trials for reducing the incidence of prostate cancer in men with precancerous lesions and for treating the side effects of prostate cancer therapy; Andarine is in trials for treating cancer-associated cachexia. On. Feb. 2, priced 5.4M shares at $14.50 per share for gross proceeds of $78.3M. Underwriters: Goldman, Sachs & Co. (lead), SG Cowen Securities, and Lazard Freres & Co. First-day change: -11%.

§ Jan. 29, 2004: Eyetech Pharmaceuticals Inc. (NASDAQ:EYET): Developing therapeutics for diseases of the eye. The lead product, Macugen (an anti-vascular endothelial growth factor aptamer), is being tested in two Phase III clinical trials in wet age-related macular degeneration and a Phase II trial in diabetic macular edema. On Jan. 29, priced 6.5M shares at $21 per share for gross proceeds of $136.5M. On Feb. 4, raised an additional $20.5M by selling the full overallotment (975,000 shares). Total gross proceeds: $157M. Underwriters: Merrill Lynch & Co. and Morgan Stanley (joint book-running managers); Bear, Stearns & Co.; and Credit Suisse First Boston. First-day change: +54%.

Completed Follow-Ons

§ Dec. 16, 2004: Serologicals Corp. (NASDAQ:SERO) priced a follow-on offering of 4.2M shares at $22.80 per share for gross proceeds to the company of $95.8M. As well, selling stockholders sold 1,362,860 shares for gross proceeds of $31M. On Dec. 21, the company raised an additional $14.3M by selling the full overallotment (630,000 shares). Total gross proceeds to the company: $110.1M. Underwriters: J.P. Morgan Securities (book-running manager); Banc of America Securities; and Pacific Growth Equities.

§ Dec. 9, 2004: Array BioPharma Inc. (NASDAQ:ARRY) priced a follow-on offering of 8M shares at $7.75 per share for gross proceeds of $62M. On Dec. 14, raised an additional $9.3M by selling the full overallotment (1.2M shares). Total gross proceeds: $71.3M. Underwriters: UBS Investment Bank (book-running manager); Legg Mason Wood Walker; Piper Jaffray; and Thomas Weisel Partners.

§ Dec. 9, 2004: Nastech Pharmaceutical Company Inc. (NASDAQ:NSTK) priced a follow-on offering of 4.25M shares at $13.50 per share for gross proceeds of $57.4M. Underwriters: Citigroup Global Markets (book-running manager); Needham & Co. (co-lead); WR Hambrecht+Co.; and Delafield Hambrecht.

§ Dec. 8, 2004: NitroMed Inc. (NASDAQ:NTMD) priced a follow-on offering of 3,247,878 shares at $24.46 per share for gross proceeds of $79.4M. On Dec. 20, raised an additional $8.1M by selling 331,598 shares (partial overallotment). Total gross proceeds: $87.5M. Underwriters: J.P. Morgan Securities and Pacific Growth Equities (joint book-runners); Deutsche Bank Securities; and Bear Stearns & Co.

§ Nov. 22, 2004: Cubist Pharmaceuticals Inc. (NASDAQ:CBST) priced a follow-on offering of 9,316,700 shares at $11.20 per share for gross proceeds of $104.3M. On Nov. 29, raised an additional $15.7M by selling the full overallotment (1,397,500 shares). Total gross proceeds: $120M. Underwriters: Morgan Stanley (book-runner); Pacific Growth Equities (co-lead); WR Hambrecht+Co.; Harris Nesbitt; and Wells Fargo Securities.

§ Nov. 11, 2004: Inspire Pharmaceuticals Inc. (NASDAQ:ISPH) priced a follow-on offering of 2.2M shares at $17.10 per share for gross proceeds of $37.6M. On Nov. 16, raised an additional $5.6M by selling the full overallotment (330,000 shares). Total gross proceeds: $43.2M. Underwriter: Deutsche Bank Securities.

§ Nov. 10, 2004: OSI Pharmaceuticals Inc. (NASDAQ:OSIP) priced a follow-on offering of 6M shares at $64.50 per share for gross proceeds of $387M. On Nov. 17, raised an additional $58.1M by selling the full overallotment (0.9M shares). Total gross proceeds: $445.1M. Underwriters: Merrill Lynch (sole book-runner); Morgan Stanley; Banc of America Securities; Bear, Stearns & Co.; and Lazard Freres.

§ Nov. 1, 2004: Incyte Corp. (NASDAQ:INCY) priced a follow-on offering of 9M shares at $9.75 per share for gross proceeds of $87.8M. Underwriter: Morgan Stanley & Co.

§ Oct. 29, 2004: Xcyte Therapies Inc. (NASDAQ:XCYT) priced a public offering of 2.6M shares of 6% convertible exchangeable preferred stock (which is listed under the symbol XCYTP) at $10.00 per share for gross proceeds of $26M. On Nov. 3, raised an additional $3.9M by selling the full overallotment (390,000 shares). Total gross proceeds: $29.9M. Underwriters: Piper Jaffray (lead) and JMP Securities.

§ Oct. 7, 2004: Pain Therapeutics Inc. (NASDAQ:PTIE) priced a follow-on offering of 8M shares at $7.25 per share for gross proceeds of $58M. Underwriters: Citigroup Global Markets and UBS Securities (co-leads); CIBC World Markets; and Rodman & Renshaw.

§ Sept. 30, 2004: Vicuron Pharmaceuticals Inc. (NASDAQ:MICU) priced a follow-on offering of 4.8M shares at $14.75 per share for gross proceeds of $70.8M. On Oct. 5, raised an additional $3.7M by selling 251,000 shares (partial overallotment). Total gross proceeds: $74.5M. Underwriter: Morgan Stanley.

§ Sept. 13, 2004: Encysive Pharmaceuticals Inc. (NASDAQ:ENCY) priced a follow-on offering of 4.6M shares (including the full overallotment option) at $7.94 per share for total gross proceeds of $36.5M. Underwriter: Wachovia Capital Markets.

§ July 28, 2004: Cell Therapeutics Inc. (NASDAQ:CTIC) priced a follow-on offering of 9M shares at $4.75 per share for gross proceeds of $42.8M. On Aug. 31, raised an additional $6.4M by selling the full overallotment (1.35M shares). Total gross proceeds: $49.2M. Underwriters: UBS Securities and CIBC World Markets (joint book-running managers); WR Hambrecht + Co.; Delafield Hambrecht; and Punk, Ziegel & Co.

§ July 27, 2004: Immtech International Inc. (AMEX:IMM) priced a follow-on offering of 782,608 shares at $10.25 per share for gross proceeds of $8M. On July 29, raised an additional $1.2M by selling the full overallotment (117,391 shares). Total gross proceeds: $9.2M. Underwriter: Jefferies & Co.

§ July 27, 2004: Inspire Pharmaceuticals Inc. (NASDAQ:ISPH) priced a follow-on offering of 6M shares at $12.00 per share for gross proceeds of $72M. On July 30, raised an additional $10.8M by selling the full overallotment (900,000 shares). Total gross proceeds: $82.8M. Underwriters: Morgan Stanley (book-running manager); Deutsche Bank Securities (co-lead); SG Cowen & Co.; and Piper Jaffray & Co.

§ July 22, 2004: Santarus Inc. (NASDAQ:SNTS) priced a follow-on offering of 6M shares at $9.50 per share for gross proceeds of $57M. On July 28, raised an additional $8.6M by selling the full overallotment (900,000 shares). Total gross proceeds: $65.6M. Underwriters: SG Cowen & Co. and UBS Investment Bank (joint book-running managers); Thomas Weisel Partners; and RBC Capital Markets.

§ July 20, 2004: Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) priced a follow-on offering of 5M shares at $15.50 per share for gross proceeds of $77.5M. On July 22, raised an additional $7.8M by selling the full overallotment (500,000 shares). Total gross proceeds: $85.3M. Underwriters: Morgan Stanley (sole book-running manager) and SG Cowen & Co.

§ July 1, 2004: Guilford Pharmaceuticals Inc. (NASDAQ:GLFD) priced a follow-on offering of 10M shares at $4.50 per share for gross proceeds of $45M. Underwriters: UBS Investment Bank (lead); CIBC World Markets; and Citigroup Global Market.

§ July 1, 2004: Pharmion Corp. (NASDAQ:PHRM) priced a follow-on offering of 4.6M shares at $48.00 per share for gross proceeds of $220.8M. On July 2, raised an additional $33.1M by selling the full overallotment (690,000 shares). Total gross proceeds: $253.9M. Underwriters: Morgan Stanley & Co. (lead); Pacific Growth Equities; JPMorgan Securities; and Bear, Stearns & Co.

§ June 10, 2004: Isolagen Inc. (AMEX:ILE) priced a follow-on offering of 7M shares at $8.50 per share for gross proceeds of $59.5M. On June 16, the company raised an additional $1.7M by selling 200,000 shares (partial overallotment). Total gross proceeds to the company: $61.2M. As well, selling stockholders raised $7.2M by selling 850,000 shares (together with the company’s 200,000 shares, the full overallotment). Underwriters: CIBC World Markets (sole bookrunner), Legg Mason Wood Walker (co-lead), and Adams, Harkness & Hill.

§ June 4, 2004: Myriad Genetics Inc. (NASDAQ:MYGN) priced a follow-on offering of 3.4M shares at $15.25 per share for gross proceeds of $51.9M. Underwriter: Morgan Stanley & Co.

§ May 27, 2004: Genitope Corp. (NASDAQ:GTOP) priced a follow-on offering of 6,098,823 shares at $8.50 per share for gross proceeds of $51.8M. On June 2, raised an additional $7.8M by selling the full overallotment (914,823 shares). Total gross proceeds: $59.6M. Underwriters: WR Hambrecht + Co. (lead); Punk, Ziegel & Co.; Brean Murray & Co.; and Stanford Group.

§ May 26, 2004: Avanir Pharmaceuticals (AMEX:AVN) priced a follow-on offering of 19,685,040 shares at $1.27 per share for gross proceeds of $25M. On June 10, raised an additional $3.8M by selling the full overallotment (2,952,756 shares). Total gross proceeds: $28.8M. Underwriter: Lazard Freres & Co.

§ May 5, 2004: IntraBiotics Pharmaceuticals Inc. (NASDAQ:IBPI) priced a follow-on offering of 3M shares at $13.00 per share for gross proceeds of $39M. On June 3, raised an additional $5.9M by selling the full overallotment (450,000 shares). Total gross proceeds: $44.9M. Underwriters: Deutsche Bank Securities (lead), Piper Jaffray, and Lazard Freres & Co.

§ April 23, 2004: Bruker BioSciences Corp. (NASDAQ:BRKR) priced a follow-on offering of 3M shares at $4.50 per share for gross proceeds to the company of $13.5M. As well, selling stockholders sold 12M shares for gross proceeds of $54M. Underwriters: Bear, Stearns & Co. and UBS Securities (joint book-runners) and SG Cowen.

§ April 2, 2004: Pharmacyclics Inc. (NASDAQ:PCYC) priced a follow-on offering of 2,782,609 shares at $13.00 per share for gross proceeds of $36.2M. On April 5, raised an additional $5.4M by selling the full overallotment option (417,391 shares). Total gross proceeds: $41.6M. Underwriter: Pacific Growth Equities.

§ April 2, 2004: Cypress Bioscience Inc. (NASDAQ:CYPB) priced a follow-on offering of 6M shares at $11.50 per share for gross proceeds of $69M. On April 7, raised an additional $10.4M by selling the full overallotment (0.9M shares). Total gross proceeds: $79.4M. Underwriters: Deutsche Bank Securities (lead), CIBC World Markets, Lazard Freres & Co. and Jefferies & Co.

§ March 30, 2004: Discovery Laboratories Inc. (NASDAQ:DSCO) priced a follow-on offering of 2.2M shares at $11.00 per share for gross proceeds of $24.2M. Underwriter: Bear, Stearns & Co.

§ March 24, 2004: ARIAD Pharmaceuticals Inc. (NASDAQ:ARIA) priced a follow-on offering of 4.4M shares at $8.50 per share for gross proceeds of $37.4M. On March 29, raised an additional $5.6M by selling the full overallotment (660,000 shares). Total gross proceeds: $43M. Underwriters: Lehman Brothers (lead); Lazard Freres & Co.; Adams, Harkness & Hill; JMP Securities; and Rodman & Renshaw.

§ March 17, 2004: Cell Genesys Inc. (NASDAQ:CEGE) priced a follow-on offering of 4.25M shares at $12.50 per share for gross proceeds of $53.1M. On March 23, raised an additional $8M by selling the full overallotment (637,500 shares). Total gross proceeds: $61.1M. Underwriters: JPMorgan and Lehman Brothers (joint book-running managers), Needham & Co. and SG Cowen Securities.

§ March 3, 2004: Nuvelo Inc. (NASDAQ:NUVO) priced a follow-on offering of 5M shares at $13 per share for gross proceeds of $65M. On March 8, raised an additional $9.8M by selling the full overallotment (750,000 shares). Total gross proceeds: $74.8M. Underwriters: UBS Securities (lead), CIBC World Markets, Needham & Co., and JMP Securities.

§ Feb. 27, 2004: Aphton Corp. (NASDAQ:APHT) priced a follow-on offering of 7M shares at $6.50 per share for gross proceeds of $45.5M. On March 5, raised an additional $6.8M by selling the full overallotment (1.05M shares). Total gross proceeds: $52.3M. Underwriters: UBS Securities (lead) and Harris Nesbitt Gerard.

§ Feb. 20, 2004: La Jolla Pharmaceutical Co. (NASDAQ:LJPC) priced a follow-on offering of 8,695,653 shares at $3.15 per share for gross proceeds of $27.4M. On March 5, raised an additional $4.1M by selling the full overallotment (1,304,347 shares). Total gross proceeds: $31.5M. Underwriter: Pacific Growth Equities.

§ Feb. 20, 2004: Rigel Pharmaceuticals Inc. (NASDAQ:RIGL) priced a follow-on offering of 2.85M shares at $20 per share for gross proceeds to the company of $57M. As well, selling stockholders sold 315,000 shares for gross proceeds of $6.3M. On March 25, the company raised an additional $5.7M by selling 285,075 shares (partial overallotment). The selling stockholders also sold 31,675 shares (partial overallotment) for gross proceeds of $0.6M. Total gross proceeds to Rigel: $62.7M. Underwriters: Credit Suisse First Boston (lead), Needham & Co., Thomas Weisel Partners, and Fortis Securities.

§ Feb. 12, 2004: Cepheid (NASDAQ:CPHD) priced a follow-on offering of 5.5M shares at $11.25 per share for gross proceeds of $61.9M. Underwriters: UBS Securities (lead); William Blair & Co.; C.E. Unterberg, Towbin; and Rodman & Renshaw.

§ Feb. 5, 2004: Seattle Genetics Inc. (NASDAQ:SGEN) priced a follow-on offering of 7M shares at $8.25 per share for gross proceeds of $57.8M. On Feb. 10, raised an additional $8.6M by selling the full overallotment (1.05M shares). Total gross proceeds: $66.4M. Underwriters: CIBC World Markets and Banc of America Securities (joint book-running managers) and WR Hambrecht + Co.

§ Feb. 4, 2004: EXACT Sciences Corp. (NASDAQ:EXAS) priced a follow-on offering of 6M shares at $6.75 per share for gross proceeds of $40.5M. On Feb. 10, raised an additional $6.1M by selling the full overallotment option (0.9M shares). Total gross proceeds: $46.6M. Underwriters: Merrill Lynch & Co. and UBS Securities (joint book-running managers), Thomas Weisel Partners, and Leerink Swann & Co.

§ Feb. 3, 2004: Antigenics Inc. (NASDAQ:AGEN) priced a follow-on offering of 5M shares at $10.50 per share for gross proceeds of $52.5M. On Feb. 18, raised an additional $4.2M by selling 0.4M shares (partial overallotment). Total gross proceeds: $56.7M. Underwriters: UBS Securities (lead), Needham & Co. and Ryan Beck & Co.

§ Feb. 3, 2004: Onyx Pharmaceuticals Inc. (NASDAQ:ONXX) priced a follow-on offering of 4.637M shares at $33.75 per share for gross proceeds of $156.5M. In March, raised an additional $1.6M by selling 48,693 shares (partial overallotment). Total gross proceeds: $158.1M. Underwriters: Morgan Stanley & Co. (lead), Piper Jaffray, SG Cowen Securities and Leerick Swann & Co.

§ Jan. 27, 2004: Dendreon Corp. (NASDAQ:DNDN) ) priced a follow-on offering of 10.25M shares at $12.75 per share for gross proceeds of $130.7 million. On Feb. 4, raised an additional $19.3M by selling the full overallotment (1,514,705 shares). Total gross proceeds: $150M. Underwriters: UBS Securities (lead), Needham & Co., Piper Jaffray, and Lazard Freres & Co.

§ Jan. 22, 2004: NeoPharm Inc. (NASDAQ:NEOL) priced a follow-on offering of 3.75M shares at $18.25 per share for gross proceeds of $68.4M. On Jan. 27, raised an additional $10.3M by selling the full overallotment (562,500 shares). Total gross proceeds: $78.7M. Underwriters: UBS Securities (lead), Robert W. Baird & Co., First Albany Capital, and JMP Securities.

Postponements And Withdrawals